>R&D >Message from R&D Leaders >Message from Tadataka Yamada, M.D. Chief Medical & Scientific Officer

Message from Tadataka Yamada, M.D. Chief Medical & Scientific Officer

Takeda will lead the pharmaceutical industry in providing meaningful
solutions to patients with unmet medical needs.

A Patient-Centered Approach to R&D

Tadataka Yamada, M.D.
Director and Chief Medical & Scientific Officer

In order to meet the unmet medical needs of patients around the world, Takeda has made steady progress to improve R&D productivity and continue to discover and deliver innovative medicines, with the R&D strategy focusing on two key initiatives, Quality of Thought and Operational Excellence. These initiatives build upon the four R&D guiding principles: Urgency, Innovation, Measurement and Partnership.

Building a Competitive R&D Pipeline Portfolio in Core Therapeutic Areas

Takeda is focusing resources on the core therapeutic areas of “Cardiovascular & Metabolic,” “Oncology,” “Central Nervous System,” “Immunology & Respiratory,” “General Medicine,” and “Vaccine.” In addition to promoting R&D in new drugs and vaccines in therapeutic areas where medical needs are not adequately met, we also will build a competitive pipeline by creating important treatments that span multiple therapeutic areas.

Improvement of R&D Productivity

Under the Mid-Range Growth Strategy, we have implemented various measures to boost R&D productivity.

In the short term, Takeda will focus on key late-stage assets, and on making steady progress toward regulatory approval. We will strive to maximize the value of the late-stage pipeline, including life-cycle management initiatives. In the medium term, Takeda will progress the early-stage portfolio as quickly as possible, and will pursue opportunities to in-license promising assets that are ready for POC&C (Proof of Concept & Competitiveness) testing and for new and additional indications for existing assets.

In the long term, Takeda will continue to invest in cutting-edge science and technology that will invigorate future drug discovery, and will strengthen collaborations with external consortia and research institutions. In addition, we will further improve our R&D productivity, maximizing our drug discovery potential by empowering our talented scientists and conducting critical experiments that allow the right decisions to be made at an early stage. We will also advance our capabilities in experimental and translational medicine.

Global Health Project

Takeda brings a true sense of urgency to improving people’s lives and meeting important medical needs all over the world. To this end, we are promoting the “Global Health Project,” aimed at providing people around the world with better access to medicines. As part of this initiative, we are also an active partner in Japan’s Global Health Innovative Technology Fund (GHIT Fund).* In addition, we entered into agreements with the Medicines for Malaria Venture (MMV) to study anti-malarial compounds in December 2013 as one of the projects selected to receive assistance.

Takeda is already a leader in innovative treatments for non-communicable diseases (NCDs) such as diabetes and cardiovascular disease. In this field and in areas including vaccines, we continue to engage in activities that go beyond monetary donations to promote lasting change.

  • *The GHIT Fund is a pioneering non-profit public-private partnership established in Japan in April 2013 by the Government of Japan, a consortium of five Japanese pharmaceutical companies including Takeda, and the Bill & Melinda Gates Foundation, aimed at promoting the discovery and development of new drugs to fight communicable diseases (CDs) in developing countries.